Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Oncolytics Biotech Inc (TSX: ONC )

1.690 +0.020 (+1.20%)
Streaming Delayed Price Updated: 3:59 PM EDT, Mar 27, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 13,017
Open 1.680
Bid (Size) 1.680 (5)
Ask (Size) 1.710 (6)
Prev. Close 1.670
Today's Range 1.680 - 1.720
52wk Range 1.060 - 3.100
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Evolution of Oncology Treatments Giving New Hope to Those Diagnosed with Breast Cancer
FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 24, 2023 – USA News Group – Treatments for various forms of breast cancer continue to evolve, with several new breakthroughs... 
Via FinancialNewsMedia
Rise in Biotech Innovations Generating Hope as Pancreatic Cancer Survival Rates Climb
FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 14, 2023 – USA News Group – Optimism is on the rise as the American Cancer Society is reporting that the five-year survival... 
Via FinancialNewsMedia
Exposures Product Safety

Performance

YTD
-23.53%
-23.53%
1 Month
-21.40%
-21.40%
3 Month
-20.66%
-20.66%
6 Month
+1.81%
+1.81%
1 Year
-15.08%
-15.08%

More News

Read More
Oncolytics Biotech’s® Chinese Development Partner Adlai Nortye Presents Interim Clinical Data Further Demonstrating the Anti-Cancer Activity of Pelareorep-Paclitaxel Combination Therapy in HR+/HER2- Metastatic Breast Cancer at the San Antonio Breast
Via FinancialNewsMedia
Biotechs Race for New Treatments as Breast Cancer Therapeutics Market Could Reach $15 Billion by 2028
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence COVID-19
Wave of FDA Fast Track Designations Sparks Renewed Interest in Biotech Sector That’s Heating Up
Via FinancialNewsMedia
Exposures Product Safety
Optimism Building for Advancing Pancreatic Cancer Treatment Therapies
Via FinancialNewsMedia
Exposures Product Safety
Oncolytics Biotech® Receives FDA Fast Track Designation for the Treatment of Advanced/Metastatic Pancreatic Cancer
Via FinancialNewsMedia
Exposures Product Safety
Big Developments Set to be Unveiled at This Year’s San Antonio Breast Cancer Symposium (SABCS)
Via FinancialNewsMedia
Biotech Sector Witnessing Growing Revenue Potential in Ongoing Battle Against Pancreatic Cancer
Via FinancialNewsMedia
Topics Death
Exposures Death
Biotech Sector Gaining Wins Against Pancreatic Cancer with Early Detection and New Therapies
Via FinancialNewsMedia
Biotechs with Evolving Therapies Have Potential to Revolutionize Treatments for Pancreatic Cancer
Via FinancialNewsMedia
Oncolytics Biotech® Presents Updated Clinical Data at SITC Annual Meeting Showing a 69% Objective Response Rate and Confirmed Complete Response in GOBLET Study’s Pancreatic Cancer Cohort
Via FinancialNewsMedia
Rising Incidence of Pancreatic Cancer Driving Demand for Advanced Treatment Therapies
Via FinancialNewsMedia
Exposures COVID-19
Oncolytics Biotech® Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 37th Annual Meeting
Via FinancialNewsMedia
R&D Efforts to Improve Optimal Treatments for Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Progressing
Via FinancialNewsMedia
Topics Death
Exposures Death
Oncolytics Biotech® and SOLTI Present New Clinical Biomarker Data Demonstrating Pelareorep’s Potential to Improve the Prognosis of Breast Cancer Patients at the ESMO Breast Cancer Meeting
Via FinancialNewsMedia
Global Pancreatic Cancer Therapeutics & Diagnostics Market Expected To Reach $5.6 Billion By 2027
Via FinancialNewsMedia
Promising Results Continue to Develop Optimism in Fight Against Cancers
Via FinancialNewsMedia
HER2-Targeted Therapies Introduced Early in Breast Cancer Treatment Offering Hope for Patients
Via FinancialNewsMedia
Exposures COVID-19
Oncolytics Biotech® Partner Adlai Nortye Advances to the Second Dose Escalation Cohort of the Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel Combination Treatment in Breast Cancer
Via FinancialNewsMedia
Advancements of CAR-T Cell Therapies Importance Grows While Cancer Cases Increasing
Via FinancialNewsMedia
Billions Flowing into Cancer Immunotherapy as Market Responds to Impressive Market Potential
Via FinancialNewsMedia
Optimism Builds for Promising Developments & New Drug Therapies Targeting Treatments for Breast Cancer
Via FinancialNewsMedia
Groundbreaking Clinical Trials Accelerating New Treatment Options for Pancreatic Cancer
Via FinancialNewsMedia
R&D Spending Increases Exponentially for Higher Standard of Breast Cancer Drug Treatments
Via FinancialNewsMedia
Topics Death Intellectual Property
Exposures Death Intellectual Property
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.